Skip to Main Content

Paper Details

Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
J Clin Oncol
10
2023
Circulating Tumor DNA, FN, FN-RMS, FP, FP-RMS, IR, IR RMS, Patients, RMS, Rhabdomyosarcoma, circulating tumor DNA, ctDNA, fusion-positive rhabdomyosarcoma, nucleotide, nucleotide variants, patients, rhabdomyosarcoma, single-nucleotide variants
Author NameAffiliation
Junko TsujiBroad Institute of Harvard and MIT
Donald A Barkauskas
Donald A BarkauskasKeck School of Medicine of the University of Southern California
Donald A Barkauskas
Donald A BarkauskasKeck School of Medicine of the University of Southern California
Aaron R Thorner
Jack F ShernCenter for Cancer Research, National Institutes of Health
Jack F ShernCenter for Cancer Research, National Institutes of Health
Steven G DuBois
Douglas S HawkinsSeattle Children's Hospital
Brian D Crompton
Brian D CromptonBroad Institute of Harvard and MIT
  • 1 - 12

Datasets

Release 1.2